MoonLake announces completed submission of HS BLA to U.S. FDA for its nanobody Sonelokimab | MoonLake Immunotherapeutics

MoonLake announces completed submission of HS BLA to U.S. FDA for its nanobody Sonelokimab

Sep 30 2026

MoonLake announces completed submission of HS BLA to U.S. FDA for its nanobody Sonelokimab 92.8 KB

Back to Press Releases +